ArcticZymes Leverages Rising Interest in Salt-Active Nucleases with New Whitepaper on Advancing Viral Vector Manufacturing
ArcticZymes Leverages Rising Interest in Salt-Active Nucleases with New Whitepaper on Advancing Viral Vector Manufacturing
ArcticZymes Technologies launches AZtaq™ DNA Polymerase
Tromsø, Norway, August 10th, 2023 – ArcticZymes Technologies ASA (OSE: AZT) launches AZtaq™ DNA Polymerase. ArcticZymes Technologies (AZT) today announces the launch of its new product, AZtaq™ DNA Polymerase. AZtaq™ is a high-quality thermostable DNA polymerase suitable for use in polymerase chain reaction (PCR) applications. Launching the AZtaq™ is a natural expansion of the Company’s molecular tools portfolio. Being an
Notice of Annual General Meeting
The annual general meeting (“AGM”) in ArcticZymes Technologies ASA will be held on Tuesday 06. June 2023 at 12.00 CET. The meeting will be held as a virtual meeting, with an option for shareholders to participate digitally. Please click HERE for the notice and appendicies Shareholders who wish to attend the AGM, in person, electronically or by proxy, are requested to
ArcticZymes Technologies has filed DMF for SAN HQ GMP
Tromsø, Norway, June 29th 2023 – ArcticZymes Technologies ASA (OSE:AZT) announces the filing of a Drug Master File (DMF) to the US Food and Drug Administration (FDA) for Salt Active Nuclease High Quality GMP Grade (SAN HQ GMP). ArcticZymes is pleased to announce the filing of a DMF (Type II) for SAN HQ GMP with the US FDA’s Center for
Q1 2023 Results and presentation
Tromsø, Norway, 03rd May 2023 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 31.2 million and an EBITDA of NOK 6.1 million for the first quarter of 2023. Highlights from Q1 2023 ArcticZymes Technologies (AZT) had Q1 sales of NOK 31.2 million (Q1 2022: NOK 49.2 million, NOK 35.2 million adjusted for Covid effects in Q1 2022) AZT had